Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome (II) + 5-FU/LV + Bevacizumab in mCRC
NCT06643793Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome in metastatic colorectal cancer (mCRC), sponsored by Affiliated Hospital of Nantong University. Started Nov 2024; status: recruiting.
02
Drugs
irinotecan liposome
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06643793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643793.